A group of compounding pharmacies has filed a lawsuit against the FDA, challenging the agency’s decision to remove semaglutide — which is used to treat Type 2 diabetes and obesity — from the drug ...

The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years of being considered in shortage by the Food and Drug Administration (FDA).

Earlier this month the US Food and Drug Administration removed a top weight-loss drug from its shortage list, threatening the business of GLP-1 drug compounders and some telehealth providers. A ...

Typically when a new drug comes on the market, physicians are conservative about their prescribing habits, but this has not been the case with some the latest weight loss drugs, according to the ...

Add Yahoo as a preferred source to see more of our stories on Google. After years of ongoing shortages due to their growing popularity, all doses of both Ozempic and Wegovy are now listed as ...

Ozempic and similar drugs for Type 2 diabetes and weight loss are in such high demand that the drugmakers have had a hard time keeping up. So compounding pharmacies stepped in to fill the gap, making ...

With hundreds of drug shortages persisting across the U.S., pharmacy leaders are adopting more coordinated strategies to manage supply disruptions and mitigate financial losses. These include ...

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed from the Food and Drug Administration’s (FDA) drug shortage list nearly ...

Feb 21 (Reuters) - The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's NOVOb.CO popular weight-loss and diabetes drugs, Wegovy and Ozempic, a ...